Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs GPC3-CAR-T (Primary)
- Indications Liver cancer
- Focus Adverse reactions; First in man
- 06 Jun 2017 Preliminary safety and efficacy results, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 25 Apr 2017 Status changed from recruiting to discontinued for reason not related to safety, efficacy, feasibility, or funding issues.
- 04 Apr 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.